Key Takeaways
- • Incubate founder John Stanford says the IRA's nine-year small-molecule versus 13-year biologic price-negotiation clock has pulled roughly $8 billion out of small-molecule investment, according to Incubate's Life Science Investment Tracker.
- • Incubate's tracker, drawing on more than 300 public filings, attributes 26 discontinued drug development programs and 56 halted research programs to the Inflation Reduction Act.
- • FDA review instability leads venture firms to hold about 40% of committed capital in reserve, shrinking the funds that reach companies, Stanford said.
- • Stanford backs the bipartisan EPIC Act to equalize the price-control clock at 13 years and warns that a "five and five" structure would be fatal to the venture sector.
- • Biotech CEOs raising capital should present a post-IRA net present value, a mapped patient population, and a plan to capture full value within nine years.
Summary
John Stanford, founder and executive director of the life-science venture advocacy group Incubate, told The Bio Report that Washington policy now factors directly into biotech valuations. The core driver is the Inflation Reduction Act's timing for Medicare price negotiation: small molecules become eligible after nine years on the market, while biologics wait thirteen. Stanford estimates roughly 50% of drug revenue arrives in years nine through thirteen, so the shorter clock forces investors to weigh a sharp loss of net present value against the pill.
Incubate's Life Science Investment Tracker, now in its third iteration, logs 10-K and S-1 filings that cite the IRA. According to the group, the law has been linked to 26 discontinued drug development programs and 56 halted research programs, and Incubate estimates about $8 billion less small-molecule investment than would otherwise be expected. Stanford cites Alnylam as a company that attributed a halted Phase 3 program to the law. He acknowledges that FDA approvals have not declined, arguing approvals are "the tip of the iceberg."
Stanford also highlighted FDA instability as a growing cost. Venture firms, he said, hold about 40% of committed capital in reserve when review timelines are unpredictable, reducing the capital available to companies and tightening terms. He credited Acting Commissioner Diamantis with steps toward clarity but said the agency cannot quickly rehire career staff, a challenge he expects to persist for whoever leads the FDA.
His policy prescriptions include the EPIC Act, a modernized and better-staffed FDA, and a centralized U.S. health data repository to keep AI-driven drug discovery domestic. He also argued that China has become a serious competitor, noting its regulator cut review times from about five years to roughly 12 to 13 months within a decade. For CEOs, Stanford's guidance is that investors now expect policy literacy, including a post-IRA net present value and a view on health technology assessment, presented without letting policy dominate the pitch.
Incubate's Life Science Investment Tracker, now in its third iteration, logs 10-K and S-1 filings that cite the IRA. According to the group, the law has been linked to 26 discontinued drug development programs and 56 halted research programs, and Incubate estimates about $8 billion less small-molecule investment than would otherwise be expected. Stanford cites Alnylam as a company that attributed a halted Phase 3 program to the law. He acknowledges that FDA approvals have not declined, arguing approvals are "the tip of the iceberg."
Stanford also highlighted FDA instability as a growing cost. Venture firms, he said, hold about 40% of committed capital in reserve when review timelines are unpredictable, reducing the capital available to companies and tightening terms. He credited Acting Commissioner Diamantis with steps toward clarity but said the agency cannot quickly rehire career staff, a challenge he expects to persist for whoever leads the FDA.
His policy prescriptions include the EPIC Act, a modernized and better-staffed FDA, and a centralized U.S. health data repository to keep AI-driven drug discovery domestic. He also argued that China has become a serious competitor, noting its regulator cut review times from about five years to roughly 12 to 13 months within a decade. For CEOs, Stanford's guidance is that investors now expect policy literacy, including a post-IRA net present value and a view on health technology assessment, presented without letting policy dominate the pitch.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.